Executive Summary Richard Staines spoke with Søren Bregenholt, the new CEO of Macrophage Pharma, about the company’s strategy encompassing both immune oncology and inflammatory diseases.
To read the full article, go on https://bit.ly/398smQc
Executive Summary
Macrophage Pharma’s lead asset will advance to clinical trials next year, making a series B financing round necessary, the UK biotech’s CEO tells Scrip.
